Blueprint Medicines Corp (NASDAQ: BPMC)’s stock price has gone rise by 0.59 in comparison to its previous close of 88.38, however, the company has experienced a -3.63% decrease in its stock price over the last five trading days. Zacks Investment Research reported 2024-02-16 that While the top- and bottom-line numbers for Blueprint Medicines (BPMC) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Is It Worth Investing in Blueprint Medicines Corp (NASDAQ: BPMC) Right Now?
Moreover, the 36-month beta value for BPMC is 0.66. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BPMC is 59.80M and currently, short sellers hold a 7.31% of that float. On April 19, 2024, BPMC’s average trading volume was 768.06K shares.
BPMC’s Market Performance
BPMC stock saw an increase of -3.63% in the past week, with a monthly gain of 1.06% and a quarterly increase of 11.57%. The volatility ratio for the week is 4.94%, and the volatility levels for the last 30 days are 4.22% for Blueprint Medicines Corp (BPMC). The simple moving average for the last 20 days is -1.70% for BPMC’s stock, with a simple moving average of 28.32% for the last 200 days.
Analysts’ Opinion of BPMC
Many brokerage firms have already submitted their reports for BPMC stocks, with Oppenheimer repeating the rating for BPMC by listing it as a “Outperform.” The predicted price for BPMC in the upcoming period, according to Oppenheimer is $85 based on the research report published on October 27, 2023 of the previous year 2023.
Needham, on the other hand, stated in their research note that they expect to see BPMC reach a price target of $66, previously predicting the price at $65. The rating they have provided for BPMC stocks is “Buy” according to the report published on August 21st, 2023.
Wells Fargo gave a rating of “Overweight” to BPMC, setting the target price at $82 in the report published on July 31st of the previous year.
BPMC Trading at 0.40% from the 50-Day Moving Average
After a stumble in the market that brought BPMC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.98% of loss for the given period.
Volatility was left at 4.22%, however, over the last 30 days, the volatility rate increased by 4.94%, as shares surge +0.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +15.20% upper at present.
During the last 5 trading sessions, BPMC fell by -3.63%, which changed the moving average for the period of 200-days by +41.31% in comparison to the 20-day moving average, which settled at $90.47. In addition, Blueprint Medicines Corp saw -3.62% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BPMC starting from Landsittel Michael, who sale 5,000 shares at the price of $95.00 back on Mar 28 ’24. After this action, Landsittel Michael now owns 47,286 shares of Blueprint Medicines Corp, valued at $475,000 using the latest closing price.
Albers Jeffrey W., the Director of Blueprint Medicines Corp, sale 25,073 shares at $87.28 during a trade that took place back on Mar 20 ’24, which means that Albers Jeffrey W. is holding 176,050 shares at $2,188,264 based on the most recent closing price.
Stock Fundamentals for BPMC
Current profitability levels for the company are sitting at:
- -1.99 for the present operating margin
- 0.95 for the gross margin
The net margin for Blueprint Medicines Corp stands at -2.03. The total capital return value is set at -0.6. Equity return is now at value -157.13, with -42.26 for asset returns.
Based on Blueprint Medicines Corp (BPMC), the company’s capital structure generated 0.84 points at debt to capital in total, while cash flow to debt ratio is standing at -0.63. The debt to equity ratio resting at 5.3. The interest coverage ratio of the stock is -38.21.
Currently, EBITDA for the company is -474.61 million with net debt to EBITDA at -1.45. When we switch over and look at the enterprise to sales, we see a ratio of 24.65. The receivables turnover for the company is 5.78for trailing twelve months and the total asset turnover is 0.24. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.76.
Conclusion
To wrap up, the performance of Blueprint Medicines Corp (BPMC) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
